^
BIOMARKER:

SLC3A2 expression

i
Other names: SLC3A2, Solute Carrier Family 3 Member 2, Lymphocyte Activation Antigen 4F2 Large Subunit, 4F2 Cell-Surface Antigen Heavy Chain, Solute Carrier Family 3 (Activators Of Dibasic And Neutral Amino Acid Transport), Member 2, Antigen Identified By Monoclonal Antibodies 4F2, TRA1.10, TROP4, And T43, Solute Carrier Family 3 (Amino Acid Transporter Heavy Chain), Member, Monoclonal Antibody 44D7, CD98 Heavy Chain, MDU1, Antigen Defined By Monoclonal Antibody 4F2, Heavy Chain, Antigen Defined By Monoclona
Entrez ID:
Related biomarkers:
2ms
The LAT1 antagonists, BCH and JPH203, were used to inhibit LAT1...Breast ADS from patients with BMIs > 30 stimulated BC cell migration and invasiveness. Collectively, our findings show that obese-ADS induction of LAT1 supports mTOR hyperactivity in luminal BC cells.
Journal
|
ER (Estrogen receptor) • SLC3A2 (Solute Carrier Family 3 Member 2) • SLC7A5 (Solute Carrier Family 7 Member 5)
|
ER positive • SLC3A2 expression
|
JPH203
4ms
No association between LAT1 expression and malignant features in GEP-NENs was observed. However, an association between 4F2hc expression and the potential of malignancy in GEP-NENs was evident.
Journal
|
SLC3A2 (Solute Carrier Family 3 Member 2)
|
SLC3A2 expression
5ms
Collectively, 4F2hc contributed significantly to prostate cancer (PC) progression. 4F2hc may be a novel marker and therapeutic target in PC.
Journal
|
SLC3A2 (Solute Carrier Family 3 Member 2) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • SKP2 (S-phase kinase-associated protein 2)
|
SLC3A2 expression